Category Archives: Nano Medicine

Research Report on Healthcare Nanotechnology (Nanomedicine) Market added by In4Research consist of Growth Opportunities, Development Trends, and Forecast 2026. The Global Healthcare Nanotechnology (Nanomedicine) Market report covers a brief overview of the segments and sub-segmentations including the product types, applications, companies & regions. This report describes the overall Healthcare Nanotechnology (Nanomedicine) Market size by analyzing historical data and future forecast.

The Healthcare Nanotechnology (Nanomedicine) Market Report includes:

To Get Sample Copy of Healthcare Nanotechnology (Nanomedicine) Market Report with Complete TOC, Figures & Graphs Connect with us at https://www.in4research.com/sample-request/23369

Major Key Players Covered in The Healthcare Nanotechnology (Nanomedicine) Market Report include

Healthcare Nanotechnology (Nanomedicine) Market Segments and Sub-segments Covered in the Report are as per below:

By Type:

By Application:

For more Customization, Connect with us at https://www.in4research.com/customization/23369

Geographically, this report is segmented into several key Regions along with their respective countries, with production, consumption, revenue (million USD), and market share and growth rate of Healthcare Nanotechnology (Nanomedicine) in the following regions:

The Covid19 pandemic has transformed the market landscape. The market ecosystem has taken a directional shift in the way supply-side of the market is accessed. The report covers the aftermath of the Covid19 catastrophe.

Get the PDF to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies: https://www.in4research.com/impactC19-request/23369

Important Features that are under offering & key highlights of the Healthcare Nanotechnology (Nanomedicine) Market report:

Any Questions/Queries or need help? Speak with our analyst https://www.in4research.com/speak-to-analyst/23369

Major Points in Table of Content of Healthcare Nanotechnology (Nanomedicine) Market

Chapter 1. Research Objective

1.1 Objective, Definition & Scope

1.2 Methodology

1.3 Insights and Growth Relevancy Mapping

1.4 Data mining & efficiency

Chapter 2. Executive Summary

Chapter 3. Strategic Analysis

3.1 Healthcare Nanotechnology (Nanomedicine) Market Revenue Opportunities

3.2 Cost Optimization

3.3 Covid19 aftermath Analyst view

3.4 Healthcare Nanotechnology (Nanomedicine) Market Digital Transformation

Chapter 4. Market Dynamics

4.1 DROC

Chapter 5. Segmentation & Statistics

5.1 Segmentation Overview

5.2 Demand Forecast & Market Sizing

Chapter 6. Market Use case studies

Chapter 7. KOL Recommendations

Chapter 8. Investment Landscape

8.1 Healthcare Nanotechnology (Nanomedicine) Market Investment Analysis

8.2 Market M&A

8.3 Market Fund Raise & Other activity

Chapter 9. Healthcare Nanotechnology (Nanomedicine) Market Competitive Intelligence

9.1 Company Positioning Analysis

9.2 Competitive Strategy Analysis

Chapter 10. Company Profiles

Chapter 11. Appendix

Buy Full Report at: https://www.in4research.com/buy-now/23369

Key Benefits of the Report:

For More Details Contact Us:

Contact Name: Rohan

Email: [emailprotected]

Phone: +1 (407) 768-2028

Go here to read the rest:
Global Healthcare Nanotechnology (Nanomedicine) Market Scope 2021-2027 Industry Growth, Business Opportunity, and Leading Players Industrial IT -...

What could change in the next 5 years? 2022 is the foundation year for an unprecedented amount of collaborative research and innovation. As we move ahead, an integrated healthcare industry will create new ways to diagnose patients; prevention will actually become the cure; and technology will provide unprecedented levels of patient information, making it easier than ever before to find therapies to treat individual-specific conditions, or even specific individuals.

In the next decade, global healthcare will blur the lines between different segments, and even sectors. The traditional distinction between different parts of the healthcare industry clinical practice, diagnostics, devices and pharmaceuticals has already begun to disappear. So will the barriers between innovators, service providers and technologists.

Digital health is already changing the face of diagnosis and drug discovery. In the future, new healthcare platforms will provide remote care to patients, smart sensors will monitor body chemistry and vital signs, and identify potential disease risk. Manufacturing technology will be increasingly refined and complex but not complicated.

That artificial intelligence (AI) and machine learning (ML) will accelerate along the spectrum of healthcare is a given. Robotics and virtual reality have already begun and will continue to aid doctors in the operation theatre to conduct surgery with much higher precision. Sensors monitoring vital signs, triggering alerts and even treatment are already making their mark.

Go here to see the original:
Predictions 2022: Year of personalisation of healthcare and therapies - Fortune India

AS HEALTH professionals make diagnoses every day, patients around the world take to their keyboards to research their newfound conditions. But how often is the information that these patients need accessible to them? Most journals only publish articles written for specialist readers. However, with publications now becoming increasingly accessible, patients are reading medical publications in the hope that they can better understand how to manage their conditions and/or the treatments that could be available to them.

This is where the scientific and medical publisher Future Science Group has stepped in. The progressive publisher has recognised the unmet need for patient-oriented resources and, over the past couple of years, has started publishing plain language summaries (PLS) of technical publications in its peer-reviewed journals.

What Are Plain Language Summaries?

PLS are concise recaps of technical publications. Written for lay audiences, they unpack the complex data, jargon, and concepts covered in these publications, breaking these down into their simplest terms. The summaries blend plain language with a range of media inclusions, like infographics, videos, and audio so that non-specialist readers can understand the latest developments in specific conditions, treatments, and therapies.

Here, Future Science Group reflects on two recent studies that assess a) to what extent patients read medical publications and b) how patients use the information in these publications to manage their conditions.

Do Patients Read and Use Peer-Reviewed Medical Publications?

One example of a study into how patients research their conditions is a study conducted by the healthcare marketing research company Adelphi Research. During this study, the research team asked 100 patients who have atopic dermatitis (eczema) and 50 patient caregivers to complete a survey on the information sources they use to research the condition.

Patient Survey Responses

The study, which took place in the U.S., noted that 35% of its respondents had a college education and 33% had a graduate school education. 81% of these respondents had carried out online research to investigate their condition, 77% had accessed information from healthcare providers, and 67% had sourced medical research articles themselves. Of those familiar with medical publications, 37% actively searched for these publications, while 90% accessed freely available articles.

62% of the respondents accessed medical publications via a general internet search.

49% accessed scientific journals.

19% sourced information from a library.

13% found information on patient organisation websites.

12% found information using the free search engine PubMed.

However, only 53% of respondents felt at least relatively confident in their understanding of the medical publications. Approximately half of the respondents didnt feel the publications empowered them to get involved in decision-making processes related to their eczema or stay up to date with the latest developments surrounding their condition.

Fewer than half of the respondents felt the publications empowered them to:

Optimise their disease management.

Discuss alternative treatments with healthcare professionals.

Control their condition.

Adhere to their treatment plans.

The results of this study emphasise the clear need for peer-reviewed medical content written for patient audiences. Most scientific journals lack clarity for lay audiences, and theyre often difficult to understand. However, Plain language summaries offer a valuable solution through simple language, clear structure, and media inclusions that make difficult concepts easier to grasp for patients who want to learn more about their conditions.

What Is the Value and Feasibility of Developing Plain Language Summaries of Peer-Reviewed Articles for Patients?

Another study, this one published in Therapeutic Innovation & Regulatory Science, also involved a survey that investigated whether and how patients research their conditions. Like the Adelphi Research study, this research involved a survey that confirmed patients regularly research health-related information online: 61% of the study respondents performed general internet searches on their conditions, 57% accessed patient-specific websites, and 47% searched for articles from scientific journals.

Patient Survey Responses

55 patients provided complete responses to the survey, reporting on a variety of diseases. While 23% reported on diseases concerning the central nervous system and neurology, 22% reported on pain and inflammation, 17.5% reported on autoimmune diseases, and 17.5% reported on cancers. Most of these patients consulted physicians for information about their conditions: 62% consulted specialists, 30% consulted general practitioners, and 5% consulted nurses. That said, only 17.5% of patients relied solely on a healthcare professional for information. Most also performed general internet searches, visited patient organisation websites, and accessed print and electronic scientific journals.

Almost all patients who took part in the study agreed that they wanted their physicians to discuss new information about their conditions and possible treatments with them. While 69% reported that they wanted their doctor to share all information with them, 29% reported that they only wanted their doctor to share information that was specifically relevant to them. The remaining 2% felt that information share would be of interest but that they would find it acceptable for their doctor not to share information.

Furthermore, while 96% of the patients concluded that they would be interested in sharing health information that they had found with their doctor, 45% noted that they would only feel comfortable discussing such information if they had a solid enough understanding of the material to have a conversation about it.

To conclude, 98% of patients either agreed or strongly agreed that health-related information should be easily understandable and more accessible to patients.

Patient and Caregiver Interviews

The study also involved interviews with patients and caregivers, during which patients explained that the main reasons they were researching their conditions were to improve their knowledge of their conditions and empower themselves. All interviewees noted that they would like doctors to provide more information, especially as information from the internet isnt always reliable.

Some of the information that patients hoped to gain from their doctors included information on how their disease and its management can affect daily living, epidemiologic data that offers long-term prognostic information about their disease, and information on the relevance of data from clinical studies. The respondents also agreed that handing out PLS could help doctors build good relationships with their patients while offering reliable and trustworthy resources.

Physician Insights

Meanwhile, the physicians who took part in the study concluded that PLS play an important role in improving patient communication, especially given the limited time available during many consultations. As a result, 60% of physician respondents confirmed that they would use PLS in their patient communications.

Open-access publishing and the expansion of online platforms should make communication through PLS even easier over upcoming years. This is essential given new patient engagement concepts (like shared decision making (SDM), self-management, patient empowerment, and patient-centred care), which have been widely adopted in clinical practice over the past few years. These concepts are key to helping patients become more involved in their healthcare management.

How Plain Language Summaries Fill the Demand for Patient-Centred Resources

The advent of PLS and other patient-centred resources has fuelled the evolution of the historically paternalistic relationship between patients and healthcare professionals into a collaborative partnership. The studies discussed here reinforce the evidence that patients actively seek information about their conditions to complement the information they receive from healthcare professionals, and that there is demand for plain language content written for patient audiences.

Future Science Groups publication of PLS in its open-access journals works towards filling this demand, which is only growing. These summaries prove invaluable to both patients and healthcare professionals, playing an essential role in patient dialogue, education, and accessibility.

About Future Science Group

Future Science Groups highly regarded journals publish the latest information in a wealth of scientific and medical disciplines, spanning from oncology to regenerative medicine to nanomedicine. Aside from publishing its portfolio of 34 journals, the Group also hosts a variety of events and digital hubs, where scientific communities come together to partake in essential discussions that support developments in science and medicine.

Future Science Group has been praised for its PLS initiative, which makes clinical study results and other essential information accessible to lay audiences, ensuring that all readers can access resources that help them understand diseases, treatments, and therapies.

Read more from the original source:
The Value of Plain Language Summaries to Patients and Caregivers - The Voice Online

The World Health Organization has estimated the SARS-CoV-2 (COVID-19) pandemic to have caused more than 5.3 million deaths worldwide to date, and with the emergence of new variants, the urgency of effective immunization has never been more critical.

Study:The Importance of Nanocarrier Design and Composition for an Efficient Nanoparticle-Mediated Transdermal Vaccination. Image Credit:BaLL LunLa/Shutterstock.com

Alternative means of effective delivery have been explored in a recently published article from the journal vaccines, highlighting how nanomedicine can aid the effectiveness oftransdermal antigen delivery.

The COVID-19 infection caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2) has been catastrophic for the global population, with high rates of morbidity and mortality.

Schematic representation of the routes of skin penetration of active compounds. On the left, a transpedicular route consists of a. entry through hair follicle, b. entry through sweat glands, c. entry through sebaceous glands. On the right, transepidermal route. d. Transcellular pathway, e. Intercellular pathway.Image Credit:Valdivia-Olivares, R.,et al

The World Health Organization has estimated approximately 19.4 million infants globally have not been provided with vaccines. As the severity of the pandemic continues, the health of these children is at increased risk for deterioration.

This has led to the need to find alternative routes for immunization, which are effective and safe.

Transdermal routes of antigen delivery consist of a topical application to the skin where the active ingredients are absorbed systemically.

This type of method can be beneficial as it reduces first-pass metabolism and reduces the level of adverse effects. Transdermal administration provides an easy, simple, non-traumatic alternative that allows for self-administration, making this delivery route more attractive than the traditional injection method that involves needles.

However, a challenge for this delivery route for vaccine development consists of the protective barrier of the skin and the associated difficulties with overcoming the stratum corneum to enable antigen absorption.

Schematic representation of the mechanisms involved in immunization based on nanoparticles, either using combined techniques or design of nanoparticles by passive diffusion. Once the stratum corneum has been crossed, the antigens can interact with cells of the immune system already described. Image Credit:Valdivia-Olivares, R., et al

The skin is the largest organ in the body and consists of up to 20 million cell types, comprising but not limited tokeratinocytes, Langerhans cells, dendritic cells, T cells, and mast cells. These cells hold critical functions in the skin, contributing to immunocompetence and preventing pathogens from entering.

However, this also would prevent antigen delivery in the circumstance of vaccine development. Overcoming the stratum corneum barrier for transdermal permeability has been a focal point for researchers who have developed innovative technologies, such as iontophoresis, sonophoresis, and magnetophoresis electroporation, and laser microporation.

These methods can be effective but have their own limitations. For example, they are economically inefficient, and due to this, the most ubiquitous method for the administration of micro- and macromolecules via the skin has been the use of microneedles.

While microneedles can be effective, it is not considered to be completely needle-free and so with the emergence of the innovative field of nanotechnology, optimized nanosystems have been developed to cross the skin barrier without the dependence on invasive techniques.

Nanosystems which have been used for antigen delivery have been researched within literature and include nanoparticles and liposomes. Liposomes can be utilized effectively to transport antigens within parenteral administration;however, their use for needle-free transdermal immunization can be less effective.

This is due to their rigid structure which makes them inefficient for crossing the skin barrier, though incorporating nanotechnology within this nano-sized delivery particle, can allow this obstacle to be overcome.

Transferosomes are elastic liposomes that consist of phospholipidsthat form deformable vesicles. This mode of antigen delivery can be promising for use within the transdermal route as these particles can increase transdermal permeability in the stratum corneum in the presence of a hydration gradient.

Intriguingly, the biological makeup of transferosomes includes being highly flexible, effective for encapsulating hydrophobic and hydrophilic compounds as well peptides, and most importantly, they can pass through the pores of the skin. These key characteristics make transferosomes a perfect candidate for needle-free antigen delivery.

While there are significant benefits utilizing nanosized particles for nanovaccine development in innovative alternatives for parenteral antigen delivery within vaccinations, this area still requires further research.

Nanomedicine has innovated several fields of medicine, and this has benefitted research into the quality of patient care; however, the current state of medicine has proven immunizations of entire populations to be the most cost-effective method in disease prevention. This route can only be challenged with a collaborative effort with production laboratories to reduce production costs.

The advancement of needle-free administration would also require further research into the size and stability of nanosystems and the optimization of strategiesto tackle designs in a short space of time with limited resources, such as through utilizing computational techniques. This would be beneficial within a pandemic where resources are being shared between countries and urgent demand for solutions.

Benefitting and improving patient care should be the highest priority of medicine and with advanced nanocarrier design and innovative researchers, transdermal vaccinations could potentially become the future of disease control.

Continue reading: Antiviral Activity of Intermetallic Nanoparticles Incorporated into Polymeric Fibers.

Valdivia-Olivares, R., Rodriguez-Fernandez, M., lvarez-Figueroa, M., Kalergis, A. and Gonzlez-Aramundiz, J., (2021)The Importance of Nanocarrier Design and Composition for an Efficient Nanoparticle-Mediated Transdermal Vaccination.Vaccines, 9(12), p.1420. Available at: https://www.mdpi.com/2076-393X/9/12/1420

Gheibi Hayat, S. and Darroudi, M., (2019)Nanovaccine: A novel approach in immunization.Journal of Cellular Physiology, 234(8), pp.12530-12536. Available at: https://doi.org/10.1002/jcp.28120

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Here is the original post:
The Role of Nanomedicine in Transdermal Vaccine Alterantives - AZoNano

Chenzhong Li is a pioneer in the development of biosensors for cancer, neurological diseases and infectious disease diagnosis and treatment. He holds 16 U.S. and international patents with several more pending. (Photo by Paula Burch Celentano.)

NEW ORLEANS From Tulane University:

Tulane University professor Chenzhong Li, PhD, has been named a 2021 fellow by the National Academy of Inventors (NAI), an honor that is the highest professional distinction accorded solely to academic inventors.

Li, professor of Biomedical Engineering and Biochemistry at Tulane University School of Medicine and the School of Science and Engineering, leads advances in biochemistry and biomedical engineering research at the Center for Cellular and Molecular Diagnostics. He was one of 164 prolific academic innovators from across the world elected as an NAI Fellow this year.

The NAI Fellows Program highlights academic inventors who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on the quality of life, economic development and the welfare of society.

I am delighted to be selected for a fellowship with the National Academy of Inventors, Li said. This is an amazing moment and one of the most important in my professional career. While I have only been a part of the Tulane family for a relatively short amount of time, this recognition gives me the inspiration to improve my work even more in translational research and entrepreneurship education for our faculty and students.

Li is a pioneer in the development of biosensors for cancer, neurological diseases and infectious disease diagnosis and treatment. He holds 16 U.S. and international patents with several more pending.

Li developed a carbon fiber micro biosensor array only a few micrometers in size to find Beta-amyloid proteins, a critical biomarker for Alzheimers disease. The needle-like nano biosensor can measure the biomarker at the single neuron level to help better understand Alzheimers progression and to fast screen potential drug treatments. He has also invented new technology using nanoparticles to find markers for cancer tumor growth.

Li has also worked as a professional research associate at the startup company Adnavance Technologies, Inc. in Canada where he led an entrepreneurial effort in developing DNA biosensors for the detection of DNA mutations and DNA binding drug screenings.

Since joining Tulane in February, Li has worked with Tony Hu, PhD, the Weatherhead Presidential Chair in Biotechnology Innovation, and his lab to develop advanced diagnostics for infectious diseases including COVID and tuberculosis.

The caliber of this years class of NAI Fellows is outstanding. Each of these individuals are highly-regarded in their respective fields, said Dr. Paul R. Sanberg, FNAI, President of the NAI. The breadth and scope of their discovery is truly staggering. Im excited not only see their work continue, but also to see their knowledge influence a new era of science, technology, and innovation worldwide.

The 2021 Fellow class hails from 116 research universities and governmental and non-profit research institutes worldwide. They collectively hold over 4,800 issued U.S. patents. Among the new class of Fellows are 33 members of the National Academies of Sciences, Engineering, and Medicine, and three Nobel Laureates, as well as other honors and distinctions. Their collective body of research and entrepreneurship covers a broad range of scientific disciplines involved with technology transfer of their inventions for the benefit of society.

To date, NAI Fellows hold more than 48,000 issued U.S. patents, which have generated over 13,000 licensed technologies and companies, and created more than one million jobs. In addition, over $3 trillion in revenue has been generated based on NAI Fellow discoveries.

The National Academy of Inventors is a member organization comprising U.S. and international universities, and governmental and non-profit research institutes, with over 4,000 individual inventor members and Fellows spanning more than 250 institutions worldwide. It was founded in 2010 to recognize and encourage inventors with patents issued from the United States Patent and Trademark Office, enhance the visibility of academic technology and innovation, encourage the disclosure of intellectual property, educate, and mentor innovative students, and translate the inventions of its members to benefit society.

Originally posted here:
Tulane Professor Elected to National Academy of Inventors - bizneworleans.com

DGAP-News: MagForce AG / Key word(s): Study20.12.2021 / 08:30 The issuer is solely responsible for the content of this announcement.

MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval

Berlin, Germany and Nevada, USA, December 20, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc., announced today that enrollment of patients in Stage 2b of its pivotal U.S. study with the NanoTherm therapy system for the focal ablation of intermediate risk prostate cancer is successfully proceeding.

Following FDA approval to initiate Stage 2b with the final study protocol in November, MagForce USA, Inc. has since received the green light from the ethics commission ("Institutional Review Board", IRB) to proceed with the study at the respective centers. After IRB approval, MagForce has now enrolled the first patients into the clinical trial while continuing to reach out to pre-identified potential study participants for updated testing and preparations. Up to 100 men diagnosed with intermediate risk prostate cancer that has progressed to a stage where a clinical review and treatment change is required will be enrolled at the NanoTherm treatment centers owned and operated by MagForce.

"We are happy that enrollment in Stage 2b of our pivotal US study has successfully commenced and that the recruitment process is progressing well, despite once again surging Covid-19 cases. Stage 2b builds on the positive findings of earlier studies which demonstrated safety and efficacy of our approach and importantly, showed no treatment-related side effects frequently experienced with other therapies, such as sexual, urinary or gastrointestinal dysfunction or loss of energy. We are excited about the trials' potential results and are hopeful to be able to provide prostate cancer patients with a minimally invasive and highly accurate treatment option," said Ben Lipps, CEO of MagForce AG and MagForce USA, Inc.

Stage 2b of the single-arm pivotal study is planned to evaluate the use of NanoTherm ablation for the treatment of prostate cancer patients with intermediate grade lesions and confirm the favorable results seen in Stage 2a in a larger patient population. The trial is designed to demonstrate that the NanoTherm therapy system can focally ablate targeted prostate cancer lesions with minimal side effects. Subsequently the patients should then be able to return to active surveillance without definitive treatment, such as external beam radiation or prostatectomy.

MagForce previously reported encouraging findings from Stage 1 and 2a of its pivotal study confirming a highly favorable safety and tolerability profile. Treatment with the NanoTherm therapy system showed no unanticipated serious adverse events but only minimal treatment-related side effects, which were tolerable and similar to those commonly associated with biopsies.

Based on the current plan and conditions set out by the FDA, the clinical trial is expected to be finished in summer 2022. Following the final protocol, MagForce will submit interim data packages at 15 and 30 patients treated for FDA review, whilst treatments continue, which will be updated and submitted for approval after trial completion.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy system enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: http://www.magforce.com Get to know our Technology: video (You Tube)Stay informed and subscribe to our mailing list

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Contact:MagForce AG, Max-Planck-Strasse 3, 12489 BerlinBarbara von Frankenberg,VP Communications & Investor RelationsP +49-30-308380-77M bfrankenberg@magforce.com

20.12.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at http://www.dgap.de

View post:
MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully...